On Demand 2017 Sunday General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Bela Schick Lecture: The Future of Medicine and Allergy - Is it FINALLY a Brave New World?
  • Current Controversies: Alternative Therapies in Asthma & Allergy Management: Vitamin D, Fish Oil and Prebiotics/Probiotics
  • Regulatory Changes That Affect Allergists: USP 797; FDA Guidance, Etc. - What You Need to Do
  • Anaphylaxis: Causes, Diagnosis and Management
  • Which T2 Biologic is Best Suited for GINA 4-5 Non-responders?
  • Can We Predict Severity Risk for Food Allergy?
  • The Asthmatic Who Does Not Qualify for a T2 Biologic: What Is Next?

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 10 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Differentiate the non-IgE and IgE causes of anaphylaxis
  • Through case presentations, summarize the current treatment options
  • Discuss the pros and cons of available anaphylaxis outpatient action plans; and consider using a patient-oriented anaphylaxis preparedness questionnaire as an educational tool for patients at risk of anaphylaxis
  • Describe what biomarkers may be indicative of good response to treatment with anti-IgE
  • Discuss differences in outcomes of pivotal trials for the two approved anti-IL5 agents
  • Determine whether treatment failure with one biologic dictates lack of response to other agents
  • List similarities and differences between an ACO, an APM and an HMO
  • List challenges that may prevent fundamental changes in health care delivery systems
  • List recent advances that were proposed to improve health care delivery
  • Explain why changes to USP 797 will affect the way they practice
  • Adapt new regulatory requirements to their practices
  • Explore the meaning and risk factors of “severe” food allergy
  • Discuss biomarkers that may be associated with severity of food-allergic reactions
  • Discuss the evolution of what constitutes the infant at "high risk" for developing allergic disease
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (College) policy, the College must identify and resolve conflicts of interest for all individuals responsible for the development, management, presentation, or evaluation of content for a CME activity. Financial disclosures are reviewed in advance, to ensure any potential conflicts of interest are resolved. Disclosure in no way implies that the information presented is biased or of lesser quality; it is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Specific disclosure information for the 2017 Annual Meeting is conveniently located online at college.acaai.org/disclosures. There is a link to this information in the Annual Meeting app under Disclosures.

Course summary
Available credit: 
  • 10.00 AMA PRA Category 1 Credit™
  • 10.00 Attendance
  • 2.25 MOC
Course opens: 
10/29/2017
Course expires: 
10/29/2020
Cost:
$0.00
Rating: 
0
  • Mitchell R. Lester, MD, FACAAI
  • Larry Borish, MD, FACAAI
  • Jay Lieberman, MD, FACAAI
  • Julie Wang, MD, FACAAI
  • John J. Oppenheimer, MD, FACAAI
  • Thomas B. Casale, MD, FACAAI
  • Paul O’Byrne, MD
  • Elliot Israel, MD
  • Kevin P. McGrath, MD, FACAAI
  • J. Allen Meadows, MD, FACAAI
  • James L. Sublett, MD, FACAAI
  • Bill Finerfrock
  • Stephen A. Imbeau, MD, FACAAI
  • Matthew Greenhawt, MD, MSc, MBA, FACAAI
  • Wayne Shreffler, MD
  • David M. Fleischer, MD, FACAAI

Available Credit

  • 10.00 AMA PRA Category 1 Credit™
  • 10.00 Attendance
  • 2.25 MOC

Accreditation Period

Course opens: 
10/29/2017
Course expires: 
10/29/2020

Price

Cost:
$0.00
Please login or create an account to take this course.